t = -0.09, p = 0.93). Probable RCTs in these areas now account for 4% of all RCTs compared to 1.6% in 1956-60. Advances in mono-factorial disorders such as CF, Haemophilia, HD, MD and SCA, have tended to remain relatively constant across 50 years, whilst multi-factorial diseases such as AD and CD, continue to attract significant interest. Obesity has attracted an ever increasing number of RCTs. CONCLU-SIONS: Trials of new treatments within the selected diseases were expected to increase; however, results reported no evidence of increased research (within the selected disorders) following the identification of the causative gene(s). A greater interest appeared to be directed towards diseases with geneenvironment interaction i.e. obesity. Further development of this analysis may assist identification of genetic research investments which can translate most effectively to improved clinical practice.
PMC55 MATRIX MODEL FOR DETERMINING A DRUG'S HEALTH ECONOMIC FOCUS TO OPTIMIZE ITS ECONOMIC VIABILITY
Hemels M 1 , Einarson TR 2 1 Novo Nordisk, Bagsvaerd, Denmark, 2 University of Toronto, Toronto, ON, Canada Discovering and developing drugs is a risky process that requires a great deal of both time and money. To gain competitive advantage, companies must establish the health economic viability of the product and adapt development plans effectively to meet market access requirements. To present a conceptual model that optimizes the economic viability of potential new drugs by identifying useful properties and obtaining clinical, economic, and quality-of-life data as early as possible in the product development cycle. The matrix is formed by two drug characteristics of primary importance: indication and mechanism of action (MOA). Four scenarios arise from this matrix: I = New Market Entry (drugs having both novel MOA and indication), II = Product Development (new MOAs for existing indications), III = Market Expansion (existing MOA but new indication), and IV = Market Penetration (existing MOA and existing indication). Economic viability incorporates the following six parameters: efficacy, tolerability/safety, QOL, pricing, effectiveness, and formulation. To optimize a product's economic viability, sponsors should evaluate, based on type of scenario and its requirements for these six parameters, the health economic challenges ahead to be overcome in order to achieve successful reimbursement. Drugs in Scenario I fulfill an unmet therapeutic need and are therefore highly desired. Economic viability for these products is high. Those with novel MOAs are also highly valued, as they could treat wider ranges of patients or those who fail other regimens. Compounds in Scenario IV pose the greatest challenges for health economic viability. The product is considered a 'me too' and, therefore, there is an increased focus on added value relative to existing products. Using this matrix can identify early the optimal position of a new drug, the data required, and when the data should be collected and verified. Consequently, development can be made efficient, with reduced waste of resources and funds.
CARDIOVASCULAR DISORDERS-Clinical Outcomes Studies PCV1 A MODIFIED RXRISK-V COMORBIDITY INDEX PREDICTS ADHERENCE WITH LIPID LOWERING THERAPY (LLT)
Ghate S 1 , LaFleur J 1 , Charland SL 2 , Sauer B 1 1 University of Utah, Salt Lake City, UT, USA, 2 University of Colorado, Boulder, CO, USA OBJECTIVE: Studies have shown that increased co-morbidity is associated with poor pharmacological adherence. We undertook to determine the feasibility of using the modified RxRisk-V co-morbidity index to predict adherence to lipid lowering therapy (LLT). METHODS: Using RxAmerica data, patients Ն18 years and with Ն18 months of continuous health plan enrollment from 2001-2005 were included in the analysis if they were 'new starts' with any class of LLT, defined as no prior treatment in the class for six months. Adherence ratios (defined as proportions of drug-available days during the follow-up period) were calculated and patients with adherence ratios Ն0.80 were considered adherent to LLT. Using a modified RxRisk-V, co-morbid conditions (CCs) were identified based on one-year of prescription claims prior to the index LLT prescription. Multivariable logistic regression was used to estimate the age-and sex-adjusted odds for adherence associated with various levels of disease co-morbidity. RESULTS: A total of 19,458 patients were identified as new starts with an LLT class. The mean age of patients was 55 years (SD 12.1), 48% were females, and 43% had Ն3 CCs. Results of the regression analysis showed that patients with 1-2 CCs were less likely to be adherent (OR: 0.90; CI: 0.83-0.99) compared to patients with no CCs. Patients with Ն3 CCs were more likely to be adherent (OR: 1.10; CI: 1.01-1.18). The OR for adherence was significantly decreased for individuals with anxiety and tension, pain disorders, and tuberculosis. The OR was significantly increased for patients with cardiovascular diseases, psychiatric disorders, gastric acid disorders, and others. CONCLUSION: These results show that the relationship between adherence and degree of co-morbidity takes a U-shaped distribution; patients with lower levels of co-morbidity are less adherent compared to patients with no co-morbidity, and patients with higher levels of co-morbidity are more adherent. Patients were classified as appropriately (AM) or inappropriately managed (IAM) using baseline lipid levels and the first post-index follow-up lipid panel (goal attainment irrespective of therapy), and risk stratification per NCEP-ATP III guidelines. Post-index, Abstracts A185 stroke event incidence between groups was analyzed descriptively and through a multivariate logistic regression analysis after controlling for differences in baseline clinical and demographic variables. RESULTS: Among 8176 study patients (3493 AM; 4683 IAM), AM patients were significantly older [51.4 Ϯ 9.1 and 50.0 Ϯ 9.6 years, p < 0.01] and comprised of fewer males (43.2% vs. 56.2%; p < 0.01). AM patients were more likely to be at lower risk status at index date versus IAM patients (63% vs. 28%; p < 0.01), and had a significantly lower Deyo-Charlson comorbidity score (0.32 Ϯ 0.56 vs. 0.20 Ϯ 0.44; p < 0.01). During follow-up, fewer AM patients experienced a stroke event versus IAM patients (0.7% vs. 1.1%; p = 0.03) and thereby were 36% less likely to have a stroke event (OR: 0.64, 95% CI: 0.44-0.93; p < 0.01). CONCLUSION: Adhering to clinical guideline treatment recommendations was likely to be associated with subsequent stroke reductions and possible long-term cost savings in this managed care population.
PCV2 STROKE EVENTS IN MANAGED CARE PATIENTS MANAGED ACCORDING TO NATIONAL LIPID TREATMENT GUIDELINES

PCV3 SYSTEMATIC REVIEW OF NICARDIPINE IN NEUROVASCULAR CONDITIONS
Reddy P 1 ,Yeh YC 1 , Clapp M 2 , Churchill W 3 1 Partners Healthcare, Charlestown, MA, USA, 2 Massachusetts General Hospital, Boston, MA, USA, 3 Brigham and Women's Hospital, Boston, MA, USA OBJECTIVE: Injectable nicardipine is increasingly used in managing neurovascular conditions. To understand its place in therapy, we conducted an evidenced-based literature review.
METHODS:
The English-language literature in OVID and Cochrane databases was searched using combinations of these terms: intracerebral hemorrhage (ICH), neurology, neurosurgery, nicardipine, stroke, subarachnoid hemorrhage (SAH). Twohundred and twenty-three abstracts were identified; after independent review by two individuals, four clinical guidelines, two meta-analyses, and four randomized controlled trials (RCT) were deemed relevant. RESULTS: In clinical guidelines, based on expert opinion, nicardipine was recommended to manage hypertension in 1) ischemic stroke patients eligible for acute reperfusion therapy (alternatives: labetalol, nitropaste, and nitroprusside); and 2) ICH (alternatives: enalapril, esmolol, hydralazine, labetalol, nitroprusside, nitroglycerin). In a meta-analysis, nicardipine had no effect on death or dependency in patients with aneurysmal SAH [RR:0.97 (95%CI:0.78-1.20)]; adverse events were higher versus placebo [hypotension:34% vs. 5%; phlebitis:22% vs. 5%; pulmonary edema + azotemia: 6% vs. 2%]. In acute traumatic brain injury, nicardipine had no impact on death and severe disability [RR:0.25 (95%CI:0.05-1.27)]. Nicardipine's effect on cerebral blood flow was comparable to labetalol (+0.19 Ϯ 3.9 ml/100 g/min vs. -1.55 Ϯ 3.2 ml/100 g/min; p = 0.39) in ICH, while it increased from baseline in SAH patients (42.1 Ϯ 12.3 ml/100 g/min vs. 47 Ϯ 10.7 ml/100 g/min; p < 0.05). In a craniotomy RCT, nicardipine was less effective than labetalol in preventing emergent hypertension (50% vs. 82%; p = 0.05) and was associated with more tachycardia (20% vs. 0%; p = 0.11), hypotension (15% vs. 0%; p = 0.23) and higher cost ($23.65 Ϯ 6.62 vs. $5.23 Ϯ 2.0; p < 0.05). Mean arterial pressure remained depressed 20 minutes post-infusion compared to nitroprusside, despite lack of cumulative nicardipine plasma levels [60 Ϯ 2 mmHg vs. 73 Ϯ 4 mmHg; p < 0.05] in spinal surgery patients. CONCLU-SION: While nicardipine has a role in select neurovascular indications, recommendations are based on expert opinion. Moreover, a lack of benefit has been demonstrated in metaanalyses and RCT in other neurovascular indications, including aneurysmal SAH and acute traumatic brain injury.
PCV4 APPROPRIATE UTILIZATION AND COST-ANALYSIS OF ADD-ON EZETIMBE LIPID-LOWERING THERAPY AT THE VETERANS AFFAIRS SAN DIEGO HEALTH CARE SYSTEM (VASDHS)
Rubin LM, Bounthavong M, Christopher MLD, Morreale AP, Plowman BK, Boggie DT Veterans Affairs San Diego Healthcare System (VASDHS), San Diego, CA, USA OBJECTIVE: The current study evaluated the appropriate utilization of ezetimibe add-on therapy to simvastatin and the costconsequences based upon the following outcomes: ezetimibe response, LDL-C goal achievement, and switch to rosuvastatin. METHODS: This was a retrospective review of VASDHS medical records to identify patients with active prescriptions for ezetimibe and simvastatin between January 1, 2004 and August 31, 2007 . Base-case response was defined as Ն10% LDL-C reduction from baseline at study endpoint. Additional efficacy parameters included LDL-C goal achievement and switch to rosuvastatin if LDL-C goal not met. Pre-post analyses for continuous and binomial data were performed using Wilcoxonranked sum and McNemar's tests, respectively. Cost analyses were conducted from the payer perspective, utilizing total direct costs. Average cost-effectiveness ratios (CER) were calculated for (1) ezetimibe response, (2) LDL-C goal achievement, and (3) switch to rosuvastatin. Sensitivity analyses were performed varying the base-case response definition. RESULTS: Overall, 121 patients met inclusion. Baseline characteristics were as follows: male 97.5%; Caucasian 78.5%; CHD 67.8%; diabetes 63.6%; symptomatic CAD 15.7%; PAD 18.2%; AAA 7.4%; >20% 10-year risk-score 95.9%; LDL-C goal <100 mg/dL 95.9%; LDL-C goal <70 mg/dL 57.9%; and smoker 28.1%. Pre-post comparisons showed significant differences from baseline LDL-C and cholesterol for both responders (p < 0.001, p < 0.001) and non-responders (p = 0.028, p = 0.028). Overall, 88.4% of patients responded to ezetimibe, while 36% of nonresponders had their antilipemic regimen modified. In addition, 53% of patients reached LDL-C goal. Average CERs over a 9-month period using base-case response definition were: $1705.64 per ezetimibe response, $2054.26 per LDL-C goal achieved, and $2997.56 per switch to rosuvastatin. Sensitivity analyses showed no change in trend for ezetimibe response, but changes were observed for the latter parameters. CONCLU-SION: There is benefit in assessing both response rates as well as LDL-C goal attainment when determining a cost-analysis of ezetimibe add-on therapy to simvastatin.
PCV5 THE IMPACT OF PHARMACISTS' INTERVENTIONS: SENSITIVITY ON PATIENT OUTCOMES IN HYPERLIPIDEMIA MANAGEMENT
Machado M, Bajcar J, Nassor N, Einarson TR University of Toronto, Toronto, ON, Canada OBJECTIVE: Hyperlipidemia increases the risk for cardiovascular disease and control is pivotal for preventing subsequent complications. Multidisciplinary interventions, including pharmacists, are important for improving patients' outcomes. Our objective was to quantify the impact of pharmacist interventions in enhancing patients' clinical and humanistic outcomes. METHODS: Two reviewers searched International Pharmaceutical Abstracts, Medline, Embase, The Cochrane Central Register of Controlled Trials, 3rd Quarter and CINAHL for pharmacist interventions in hyperlipidemia. Quality was assessed using Downs-Black scale. Data extracted included patients enrolled, study characteristics, intervention type and pre-and post-
